ВПЛИВ ГРИБА GANODERMA LUCIDUM (CURT.:FR.) P. KARST. НА ГУМОРАЛЬНУ ІМУННУ ВІДПОВІДЬ У МИШЕЙ ЛІНІЇ CBA/CA З ВТОРИННИМ ІМУНОДЕФІЦИТОМ
DOI:
https://doi.org/10.11603/2312-0967.2015.2.4847Abstract
INFLUENCE OF MUSHROOM GANODERMA LUCIDUM (CURT.: FR.) P. KARST. ON THE HUMORAL IMMUNE RESPONSE IN MICE LINE CBA / Ca WITH SECONDARY IMMUNODEFICIENCY.
V.T. Pidchenko*, I.V. Nizhenkovska*, N.G. Bychkova*, N.A. Bisko**, A.Y. Rodnichenko***
*Bogomolets National medical university, Kyiv
**M.G. Kholodny Institute of Botany NASU, Kyiv
***The State Institute of Genetic and Regenerative MedicineNAMSUkraine, Kyiv
Summary: The article shows the results of the investigation of the influence of biomass powder of mushroom Ganoderma lucidum on the humoral immune response in mice line CBA / Ca in terms of the simulated secondary immunodeficiency. To simulate the immunodeficiency was used the immunosuppressant cyclophosphamide, which was administered once a dose of 150 mg / kg, intraperitoneally, the first day of the experiment. Results of the study show that the application of Ganoderma Lucidum biomass powder in mice line CBA / Ca with induced immune deficiency, causes a significant increase in the number of antibody-producing cells in the spleen and antibody levels in serum.
Key words: Ganoderma lucidum, humoral immune response, cyclophosphamide, immunodeficiency.
Introduction. Searching and development of remedies of natural origin is an actual problem today. In recent decades, basidiomycetes and biologically active substances extracted from them, attracted attention of scientists in Asia andNorth America. Ganoderma lucidum, a native biosidiomycetous fungus, has been used inChina,Japan andKorea to prevent and treat bronchitis, chronic hepatitis, hypertension, atherosclerosis, tumor growth and immunological disorders for over 2000 years. The influence of biomass powder of mushroom Ganoderma lucidum, grown by submerged cultivation, at various immunity in immunodeficient conditions is not studied. Therefore the aim of our study was to determine the influence of biomass powder of mushroom Ganoderma lucidum on humoral immune response in mice with secondary immunodeficiency in vivo.
Methods. The biomass of mushroom Ganoderma lucidum was grown by submerged cultivation. To simulate the immunodeficiency was used the immunosuppressant cyclophosphamide, which was administered once a dose of 150 mg / kg, intraperitoneally, the first day of the experiment. The number of antibody-producing cells in the spleen and antibody levels in serum were discovered. Statistical analysis of the results was performed using Student`s t-test.
Results and discussion.
The introduction of biomass powder of mushroom Ganoderma lucidum for 10 days to mice line CBA / Ca with secondary experimental immunodeficiency causes a significant increase in the number of cells in femur.
The recovery of thymus weight, relative thymus weight, thymus settlement index and number of lymphoid cells in the organ to the level of data in a group of control mice after the administration of biomass powder was not found.
The introduction of biomass powder of mushroom Ganoderma lucidum to mice line CBA / Ca with secondary experimental immunodeficiency causes a significant increase in the relative number of antibody-producing cells in the spleen in 2 times, the absolute number of antibody-producing cells in 2,1 times compared with the group of mice treated with cyclophosphamide. The antibody levels increase in 6,7 times (hemolysin titer) and 2,4 times (hemagglutinin titer).
Conclusions. Thus, the results of the study show that the introduction of biomass powder fungus Ganoderma lucidum to mice line CBA / Ca with secondary experimental immunodeficiency causes a significant increase in the number of antibody-producing cells in the spleen and antibody levels in serum, which may indicate the immunomodulatory effect of biomass powder of fungus Ganoderma lucidum on humoral immune response.
Downloads
Published
How to Cite
Issue
Section
License
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
